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Abstract
Fibromyalgia (FM) or Fibromyalgia Syndrome (FMS) is a neurodegenerative 
disorder causing musculoskeletal pain, tenderness, stiffness, fatigue, and sleep 
disorder in the body. It is one of the most common chronic pain conditions, affect ing 
about 6% of the world population. Being refractory, till date, no specific treatment 
of this disease is available. Accumulating evidences over the last few decades indicate 
that proinflammatory macrophages, cytokines, & chemokines as the key players in 
this disease. Recent findings suggest activation of Microglial cells and associated pro-
inflammatory signals as one of the major causes of chronic pain in patients suffering 
from fibromyalgia. Increased density of iNOs/CD68+ M1 effector macrophages has 
been associated with neu ropathic pain models. In light of this, depletion of these pro-
inflammatory macro phages has been shown to reduce sensitivity to neuropathic pain. 
On the other hand, modulating pattern of AGEs (Advanced Glycation End-Products) 
can also contribute to inactivation of macrophages. These findings strongly suggest 
that macrophages are critical in both inflammatory and neuropathic pain. Therefore, 
this chapter highlights the impact of macrophage plasticity in various immunopatho-
logical aspects of fibromyalgia.
Keywords: fibromyalgia, Th1/Th2 immune response, M1/M2 macrophages, 
neurodegeneration
1. Introduction
Fibromyalgia has been considered a rheumatologic disease, also known as fibro-
sitis and myofascial pain syndrome. Fibromyalgia affects the muscles, ligaments & 
tendons, and bones with no signs of inflammation of the tissue [1]. The origin of 
fibromyalgia is still not clear, although several hypotheses stated fibromyalgia condi-
tion associated with depression and brain-based neuronal dysfunctions i.e. coaxi-
ally linked with non-uniform signal transduction mechanism. Preclinical studies 
addressing the symptoms of fibromyalgia are increased levels of substance P (SP) in 
the cerebrospinal fluid (CSF) of the individuals. SP is a peptide which is composed 
of 11 amino acids and acts as a neurotransmitter. It plays a significant role in pain 
stimulations from the peripheral nervous system to the central nervous system [2]. 
Fibromyalgia patients showed a 3-fold increase in the levels of substance P in CSF 
which possibly activates neurokinin (NK) receptors that induce chronic pain [3, 4]. 
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Moreover, besides NK receptors, the excitation of amino acid receptors such as 
N-methyl D-aspartate (NMDA) receptors also leads to hyperalgesia in fibromyalgia 
[5]. This is associated with the deficiency of Dopamine during chronic pain in 
fibromyalgia [6]. It is a neurotransmitter of the Central nervous system (CNS) and 
regulates the pain processing of CNS. On the other hand, several studies indicating 
that macrophages, cytokines/chemokines, and oxidative stress are the key mediator 
of immune activation and inflammation in fibromyalgia condition [7].
Nitric oxide (NO), is a principal determinant of normal endothelial and vascular 
function. During inflammatory reactions, NO production increases considerably 
and, contributes to oxidative stress together with other reactive oxygen species (ROS) 
[8]. Macrophages that have a pro-inflammatory role are called classically-activated 
(M1) macrophages. Classically-activated (M1) macrophages are activated by 
Lipopolysaccharide (LPS) and Interferon-gamma (IFN-γ). The role of activated M1 
macrophages is to secrete pro-inflammatory cytokines and chemokines and present 
antigens [9, 10]. Cytokines produced by T helper type 1 (Th1) cells, induce the differ-
entiation of classically activated (M1) macrophages [11, 12]. Some of the pro-inflam-
matory cytokines including TNF-α, IL-1, IL-6, and IL-8 have been reportedly linked 
with the immunopathology of fibromyalgia. Prolonged activation of M1 macrophages 
has been reported to encourage neuro-inflammation which may responsible for the 
pathogenesis of neuropathic pain among the fibromyalgia patients [13–15]. There is 
no successful medication yet that has been proven to treat fibromyalgia completely.
1.1 Epidemiology
Fibromyalgia prevalence is more common among women as compared to men 
and risk increases significantly after growing age [16]. Apparently, in population 
studies indicate that there is a need for a standardized gender-based diagnostic 
approach that can allow for more reliable diagnosis and some of the gender biases 
that relate to women suffering the most. It is estimated globally that there is about 
6% of the patient that suffers from this chronic disease out of which 68 percent 
are females [17]. Patients who need tertiary care pain clinic help, more than 40% 
outcome measure is a resolution of symptoms of fibromyalgia [18]. Patients with 
existent chronic rheumatic diseases are having high risk of fibromyalgia (Figure 1).
1.2 Etiology and pathophysiology
Fibromyalgia is a chronic pain disorder but the etiology of the disease still not 
clear [19, 20]. Fibromyalgia is triggered by multiple physical and/or emotional 
stress factors. There is increasing evidence that revealed the role of macrophages 
including activated M1 macrophages, and inducible nitric oxide synthase (iNOS) 
in pain conditions in fibromyalgia [21]. Significantly, macrophages can mediate 
microglial activation through the production of pro-inflammatory cytokines such 
as IL-1β, IL-6, and TNF-α [22]. In addition, levels of pro-inflammatory cytokines 
and chemokines are enhanced in serum and could contribute to inflammation at the 
systemic level. On the other hand, alteration of central nervous system (CNS) cells 
occurs in fibromyalgia cause discomfort and sensory perception [5]. The functional 
neuroimaging technique rests crucially on the identification of pain-sensitive areas 
in regions of the Brain. Furthermore, differences in activation of pain-sensitive 
areas of the brain by functional neuroimaging techniques have been revealed in 
fibromyalgia condition. Several pharmacological studies have shown a genetic 
predisposition for fibromyalgia though there is no documentation of a definitive 
candidate gene [23]. About one-third of fibromyalgia patients have a close relative 
with rheumatic disease/fibromyalgia history (Figure 2) [24].
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1.2.1 Psychological stress and trauma
Research has also shown that stress is linked with the increasing risk of develop-
ing fibromyalgia [25]. Psychologic factors including stress, trauma, anxiety, and 
depression have been shown their role in pain severity in fibromyalgia patients 
[26, 27]. Corticotrophin-releasing hormone (CRH), is a well-known hormone for 
stress response mediators, was found high in the cerebrospinal fluid (CSF) among 
fibromyalgia patients and was linked with pain [28]. Fibromyalgiais quite common 
in individuals with mastocytosis [29] where mast cells influence the infiltration, in 
situ differentiation and inflammatory response of macrophages and neutrophils; in 
various organs. This type of rapid proliferation of mast cells causes itchy bumps on 
the skin, diarrhea, and bone pain. Emotional stress is the primary symptom among 
the individuals suffering from mastocytosis and reportedly found high serum levels 
of CRH in mastocytosis patients [30]. CRH, nerve growth factor, neurotensin and 
substance P are known as stress peptides which released in peripheral tissues like 
blood vessels, muscles, and skin during allergic, immune, and stress reaction in the 
body. In another study, upregulation of nerve growth factor in the CSF among the 
patients suffering from fibromyalgia [31] and has been considered as a target for 
analgesic therapy [32].
1.2.2 Neuro-inflammation
A correlation between macrophages and mast cells (MCs) has been revealed 
in fibromyalgia [33, 34]. Numerous studies suggested macrophages and MCs play 
a key role during the pain and inflammation [35–38]. Macrophages and MCs also 
Figure 1. 
Reason of high prevalence rate of fibromyalgia among women.
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release pro-inflammatory and neuro-sensitizing molecules such as cytokines and 
chemokines which act as modulators of nociception, and elevated pain sensitivity 
through their receptors [39–41]. In addition, a growing body of evidence indicated 
the increased levels of the pro-inflammatory chemokines in both serum and CSF of 
fibromyalgia patients [42–44]. CSF and IL-17 are also associated with pain, depres-
sion, and anxiety which are the key symptoms among the individuals suffering 
from fibromyalgia [45, 46].
1.2.3 Central sensitization
By far the most important thing to understand about the pain and fatigue 
induced by fibromyalgia is central pain sensitization. Many nociceptive dorsal root 
ganglion (DRG) neurons express pro-inflammatory cytokine and chemokine recep-
tors that are upregulated after nerve injury [47]. Long-lasting neuro-inflammation 
through the upregulation of inflammatory molecules can contribute to the ectopic 
discharge of sensory neurons, resulting in peripheral sensitization. Prolonged 
abnormal transmission of pain signaling due to peripheral sensitization triggers 
central sensitization [48–50], mediated by pain-processing neurons and activation 
of glial cells (Figure 3) [51–54]. Glial cells are activated by various neurotransmit-
ters, such as cytokines, chemokines, and nucleotides and these activated glial cells 
directly or indirectly involved in central sensitization [10, 55–58]. Moreover, these 
cells can contribute to brain inflammation and pathogenesis of different brain 
disorders [59–65].
Figure 2. 
Progression and diagnosis process of fibromyalgia.
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1.2.4 Fascia
It has been hypothesized that inflammation of fascia is a secondary source of 
the increased pain transmitting to the spinal cord. Fascia is the thick connective 
tissue surrounding the cells of the muscles etc. The fascial system covers every part 
of a muscle and is a thick gel of ground material that suspends muscle cells and 
fibers [66]. Additionally, muscle innervation is found primarily in the fascia, hence 
the fascia is highly susceptible. Muscle biopsy, cell studies of FM patients result 
in higher levels of collagen and symptoms of oxidative stress and tissue damage, 
indicating fascial inflammation. Although findings were not consistent in con-
sidering the hypothesis of fascial inflammation as the fibromyalgia etiology [67]. 
Conversely, these inflammations may be due to low growth hormone production 
and HPA axis dysfunction, resulting in increased nociception, central sensitization, 
and chronic pain [68].
1.2.5 Altered biochemistry
Substance P (SP) is an 11-amino acid peptide IS primarily responsible in the 
neurotransmission of pain to the central nervous system (CNS). Substance P 
(SP) is associated with chronic pain found to be elevated with fibromyalgia in the 
cerebral spinal fluid (CSF) compared to controls [4, 5]. However, the diagnostic 
study also revealed low neurotransmitter levels involved in regulating sensory 
perception and also inhibit pain transmission, such as serotonin, norepinephrine, 
and dopamine, etc.
1.2.6 Nitric oxide synthase (NOS)
Fibromyalgia patients have higher oxidative stress index and lower total nitrite 
levels than healthy controls [69, 70]. NO plays a crucial role in chronic pain states with 
Figure 3. 




Pathogenic role of Th1 primed (iNOS+) macrophages and mast cells during progression of fibromyalgia.
cyclooxygenase-2 (COX-2) as termed in central sensitization [71]. Numerous studies 
considered NO as an important neurotransmitter involved in the pain and sensitiza-
tion pathways related to NOS activation. Therefore, the NO can actively participate 
in the hyper sensitization in patients with fibromyalgia. The NO is synthesized by 
the nitric oxide synthase (NOS) enzyme which has four isoforms i.e. neuronal nitric 
oxide synthase (nNOS), endothelial nitric oxide synthase (eNOS), mitochondrial 
nitric oxide synthase (mtNOS), and inducible nitric oxide synthase (iNOS) [72, 73]. 
The nNOS, eNOS, and mtNOS are expressed in the majority of the cells. The nNOS 
and eNOS are regulated by Ca2+ fluxes, whereas iNOS is regulated by cytokines. 
iNOS is expressed only in response to some pathological stimuli typically bypro-
inflammatory cytokines and/or bacterial lipopolysaccharide (LPS) [74, 75]. Inducible 
nitric oxide synthase (iNOS) together with oxidative stress plays an important role in 
the development of vascular dysfunction in sepsis. In fibromyalgia, a key mediator 
of immune activation and inflammation is inducible nitric oxide synthase (iNOS), 
which produces nitric oxide (NO) [8]. Various studies have revealed the iNOS role 
in the development of inflammatory and neuropathic pain including fibromyalgia. 
Nitric oxide (NO) has various physiological functions such as vasodilation, muscle 
relaxation, learning, memory, neurotransmission, several degenerative processes and 
inflammation [8]. Copious amount of NO production is critical for the inflammatory 
response and the innate immune system. Overexpression or dysregulation of iNOS is 
linked with local inflammatory reactions and contributed to various human diseases 
[75, 76]. Considering this, iNOS inhibitory therapeutics could be promising for the 
treatment of neurodegenerative pain including fibromyalgia.
2. Role of activated macrophages/myeloid cells in the neuromyalgia
In turn, mast cells interplay with microglia, which are the resident macrophages 
of the central nervous system that may contribute to increased inflammation 
through the secretion of cytokines [59, 77]. The cytoplasmic receptor Nod-like 
receptor-2 (NOD2), and its adaptor-signaling molecule RIPK2, have been shown 
to be involved in the development of neuropathic pain after peripheral nerve 
injury. The activation of NOD2 signaling in peripheral macrophage mediates the 
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development of neuropathic pain through the production of a wide of pro-nocicep-
tive cytokines. The studies strongly suggest the undetermined significance of NOD2 
signaling in the development of neuropathic pain and to highlight potential new 
means of the target for preventing neuropathic pain [78]. Macrophages are impor-
tant participants in regulating neuro- inflammation (Figure 4); consequently, they 
are considered to be a common peripheral regulator of neuropathic pain [79–81].
3. Current therapies
There is no effective therapeutic approach available for fibromyalgia, but many 
drugs have been available to reduce its symptoms and pain. Patients suffering from 
fibromyalgia should integrate pharmacologic therapy with non-pharmacologic 
therapies [82]. In a study, it has been revealed that multi-component treatment 
could be effective in the short term for improving key symptoms of fibromyalgia 
including pain, fatigue, depression, and quality of life [83]. Modern medicine has 
most certainly come a long way in providing relief from the conditions and diseases 
of the day, sometimes other options can be just as helpful, if not more beneficial, 
in providing relief of fibromyalgia symptoms. Moreover, the prescription medica-
tions that are commonly used for the treatment of fibromyalgia symptoms can 
cause negative side effects that the individual must then deal with in addition to the 
problems along with symptoms of fibromyalgia. In order to regulate inflammation, 
role of macrophages is very crucial. As we described previously also, macrophages 
are important to sense damage to the tissue and initiate the recruitment of circulat-
ing leukocytes through triggering the chemokines secretion. The direct physical 
interaction stimulates production of reactive oxygen species (ROS) at the site 
of the injury. At the late stages of muscle regeneration, macrophages refrain the 
expression of both pro-inflammatory and anti-inflammatory cytokines and turned 
to a silenced mode. Conversely, interleukin 4 (IL-4) actions are considered to be 
regulated by the inhibition of pro inflammatory mediators. In a study, IL-4 blood 
levels were found reduced among the patients suffering with chronic widespread 
pain including fibromyalgia when compared with controls [84, 85]. Several study 
indicating that the endogenous opioid system is essential to the actions of IL-4 and 
M2 macrophages in pain control [21]. Concluding this, macrophages play a central 
role in the regulation of inflammation from the beginning to the end. This is a 
timely area of research to explore the role of macrophages particularly M2 macro-
phages which sounds more promising for tackling pathological pain.
However, there are some alternative therapeutic approaches to fibromyalgia that 
have been proven by research to aid in providing relief from its symptoms (Figure 5).
3.1 Non-pharmacologic therapy
Patients diagnosed with fibromyalgia must know their illness before starting 
their medications [86–88]. It was found that educational intervention had signifi-
cantly better improvement among fibromyalgia patients [82]. In another study, 
fibromyalgia patients reduce the fear of pain and fear of disease complications using 
cognitive behavioral therapy [83]. Cardio exercise is suggested for fibromyalgia 
patients as it helps to improve the sleep and reduce the pain as well [89, 90]. In 
a study, they uses Chinese stress reduction exercise programs and improvement 
reported among the fibromyalgia patients to reduce the key symptoms of fibromy-
algia [91, 92]. Nutritional supplementation is often used in fibromyalgia, but the 
objective findings are limited [93, 94]. Coenzyme Q₁₀supplementation in fibromyal-
gia patients improved the disease symptoms as it reduces the oxidative damage that 
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leads to muscle fatigue [95, 96]. Another study revealed that500mg L-carnitine for 
20 days has significant benefits to fibromyalgia patients which lasts up to 10 weeks 
[97]. Natural flavonoids like quercetin and luteolin giving promising results to 
reduce the key symptoms of fibromyalgia due to its anti-inflammatory, antioxidant, 
and anti-allergic property [98–101]. Moreover, flavonoids have been discussed as a 
possible treatment of central nervous system disorders [102, 103].
3.2 Pharmacologic therapy
There’s no complete cure available for fibromyalgia, but there are many medi-
cines available to treat fibromyalgia symptoms. Some drugs ease aches, fatigue, 
and pains, while others may boost your energy or improve your sleep. Fibromyalgia 
drugs mainly target pain modulatory mechanisms. There is an urgent need to 
develop new drugs targeting the fibromyalgia mechanism and treat its symptoms 
(Table 1).
4. Immune mediated therapeutic interventions
It is a well-established concept that the immune system plays a crucial role 
in various chronic pain conditions including fibromyalgia. The immune system 
involves the release of autoantibodies, pro-inflammatory cytokines, chemokines, 
substance P, histamine, tumor necrosis factor, interleukins, and prostaglandins [9]. 
In a study, IL-8 level elevated in the serum of patients suffering from fibromyalgia 
confirming the relation between fibromyalgia and higher levels of pro-inflamma-
tory cytokines [136]. In another study, the role of the NLRP3 inflammasome in 
Figure 5. 


































S.N. Drug type Drugs name Effects on 
fibromyalgia
Side-effects References
1. Antidepressants Amitriptyline Citalopram,Escitalopram, 
Fluvoxamine, Fluoxetine, Paroxetine, Sertraline
Improvement in pain, 
fatigue, and sleep
Drowsiness, Weight gain, Nausea fatigue, Dry mouth, 





Pregabalin, Gabapentin Improvement in pain, 
fatigue, and sleep
Blurry vision, dizziness, Drowsiness, Weight gain, and 
Swelling of hands/feet
[18, 28, 83, 87, 
104, 108–111]
3. Pain Relievers acetaminophen and Non-steroidal anti-
inflammatory drugs (NSAIDs) like aspirin, 
ibuprofen, naproxen, and tramadol
Improvement in aches 
and pains
Heart attack, Stroke ulcers & bleeding in the stomach, 
Intestines liver damage, Stomach pain, Constipation, 
Nausea, and Trouble concentrating
[112]
4. Muscle Relaxants Cyclobenzaprine (Flexeril) Tizanidine 
(Zanaflex)
Improvement in pain, 
fatigue, and sleep
Dry mouth, Dizziness, Blurry vision, Headaches, Chest 
pain, Nausea, and Fever
[113]
5. Serotonin inhibitors Duloxetine, Milnacipran, Reboxetine, 
Esreboxetine, Citalopram, escitalopram, 
fluoxetine, paroxetine
Improvement in pain, 
and depression
Difficulty in sleeping, Headaches, Dizziness, Blurry 




6. Gabapentinoid Pregabalin, gabapentin, Lacosamide Improvement in pain, 
fatigue, and sleep
Abnormal eye movements (continuous, & 
uncontrolled, rolling), Clumsiness, Constipation/
diarrhea, Difficulty speaking, Tiredness, Dry mouth, 
and Nausea.
[93, 104, 105, 
109, 121–124]
7. Cannabinoid Nabilone, Dronabinol Improvement in pain, 
fatigue, anxiety, and 
sleep.
Dizziness, Drowsiness, Dry mouth, Feeling “high,” 
Lightheadedness, Headache, and Insomnia
[125–128]
8. NMDA antagonist Ketamine Improvement in pain High/Low blood pressure, Increased cardiac output, 




Methotrexate, Azathioprine, Leflunomide Improvement in pain Dizziness, Headache, Tender gums, Decreased 
appetite, Reddened Eyes, and Hair Loss
[133]
10. Tumor Necrosis 
Factor (TNF) 
inhibitors
Hydroxychloroquine, Adalimumab, Golimumab, 
Certolizumab, Infliximab, Sulfasalzine and 
Etanercept
Improvement in pain, 
and fatigue
Swelling, Redness or itchy skin where your 
injection was given, A mild nose, throat or sinus 
infection,Headache, Stomach pain, and Dizziness
[134, 135]
Table 1. 
Available pharmacological interventions for fibromyalgia.
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fibromyalgia patients along with animal models was investigated. In the outcome 
of the same study, it has been revealed that increased levels of IL-1b were positively 
linked with pain in both mice and fibromyalgia patients [137]. This was the first 
of its kind study to show the relation between inflammasome and increased pro-
inflammatory cytokines among the fibromyalgia patients which confirm the direct 
link between inflammation and pain. Naltrexone and naloxoneisan antagonist 
of mu-opioid receptors and both were effective to inhibit cytokine expression 
[138, 139]. Using neuron–glia co-cultures pre-treated with naloxone and sub-
sequently treated with LPS, it was demonstrated that naloxone protects against 
lipopolysaccharide (LPS)-induced neurotoxicity through the inhibition of the 
proinflammatory factors and free radicals [139]. Similarly, naltrexone also blocked 
LPS-induced inflammation and microglial activity and inhibited TNF-α produc-
tion [139, 140]. Due to the promising preclinical data, clinical trial was conducted 
for the naltrexone and it has been found that it effectively reduced the key disease 
symptoms among the fibromyalgia patients [141]. Observational studies provide 
evidence that vagus nerve activation can down-regulated inflammation through 
nAChR-mediated inhibition of macrophage function [142–145]. Treatment with 
nicotine can inhibit the development of inflammatory cytokines release by LPS-
stimulated macrophages through the activation of α7 nAChR signaling [143, 144, 
146–148]. Following this, anti-inflammatory treatments could be promising in the 
therapeutics in fibromyalgia condition.
5. Conclusion
Fibromyalgia condition is defined by widespread musculoskeletal pain followed 
by fatigue, sleep, depression, and anxiety. The available allopathic medicines have 
their limitations and side effects and to date no permanent treatment of fibromyal-
gia is available. However, research is going on to find out more alternative options 
that can be used for treating various chronic conditions. Hence the need of the 
hour is to explore various alternative therapies for this condition. Despite various 
research and findings on fibromyalgia, it is found by most of the scientist that this 
disease is characterized by the abnormal nerve to signal transduction thus “the 
hypothesis of pain in the brain” is proven here and therefore effective neuronal 
diagnosis should be conducted before designing the treatment protocols. Thus, the 
emphasis of treatment must be in-combat with the brain to muscle co-ordinations. 
It has been well established that the immune system is an important part and plays 
a key role in the complex pathogenesis of fibromyalgia. Macrophages, inflamma-
tory cytokines, and reactive oxygen species play distinct roles in the inflammatory 
response. Inducible nitric oxide synthase (iNOS) dysregulation is implicated in 
a variety of chronic and acute diseases and inhibitors of iNOS show noteworthy 
results in animal models for septic shock, pain, and other conditions, but failed in 
clinical trials. Conversely, macrophages play a crucial role to regulate peripheral 
sensitization, cytokines, and chemokines derived from these cells and are potential 
novel therapeutic targets. Few studies were conducted in order to explore macro-
phage therapeutics in the animal model and have been shown to prevent/relieve 
neuropathic pain, but their efficacy has not yet been evaluated in clinical trials. To 
move evidence-based interventions into practice, pharmacotherapies that target 
macrophage-driven neuro-inflammation will undoubtedly open up new avenues for 
beneficial treatment of intractable neuropathic pain.
Concluding this, further research is required to clarify the role of inflammation 
and the mechanisms that regulate neuropathic pain in fibromyalgia as well as to 
shed light on potential therapeutic options.
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